David Sallman, MD

David Sallman, MD, discusses the clinical implications of the 2023 FDA approval of luspatercept for patients with very low– to intermediate-risk MDS.

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

David Sallman, MD, discusses the background of the menin inhibitor, KO-539, in acute myeloid leukemia.

David Sallman, MD, discusses the examination of magrolimab in acute myeloid leukemia.

David Sallman, MD, discusses the role of uproleselan (GMI-1271) when utilized in acute myeloid leukemia.

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

David Sallman, MD, assistant member, Moffitt Cancer Center, discusses the combination of APR-246 and azacitidine as a treatment for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.